ReviewNature reviews. Cancer2005
Immunotherapy for pancreatic cancer - science driving clinical progress.
Review in Nature reviews. Cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02021422 (A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy Regimens in Metastatic Pancreatic Ductal Adenocarcinoma Patients), which is not on this map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy Regimens in Metastatic Pancreatic Ductal Adenocarcinoma Patients
Who cites it
93 citing papers in PubMed, 202 citations in OpenAlex.
- Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Prognostic and Immunological Significance of TIPARP in Pancreatic Cancer.Digestive diseases and sciences · 2026Article
- The DIAPH3/RPL6 axis regulates the cGAS-STING pathway in pancreatic cancer.European journal of medical research · 2025Article
- Early neoplastic lesions of the pancreas: initiation, progression, and opportunities for precancer interception.The Journal of clinical investigation · 2025Review
- Pathological complete response following neoadjuvant chemotherapy with PD-1 inhibitor for locally advanced pancreatic cancer: case report.Journal of gastrointestinal oncology · 2024Article
- Comprehensive analysis and identification of prognostic biomarkers and immunotherapeutic targets in the NADPH oxidase family (and its regulatory subunits) in pancreatic ductal adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- A novel monoclonal antibody associated with glucoside kills gastric adenocarcinoma AGS cells based on glycosylation target.Journal of cellular and molecular medicine · 2022Article
- Matrix Metalloproteinase 8 Expression in a Tumour Predicts a Favourable Prognosis in Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2022Article
- MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.Oncoimmunology · 2022Article
- Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer.World journal of gastroenterology · 2021Review
- Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy.Nano-micro letters · 2021Review
- Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials.The AAPS journal · 2021Review
- Dendrimers: A New Race of Pharmaceutical Nanocarriers.BioMed research international · 2021Review
- BxPC-3-Derived Small Extracellular Vesicles Induce FOXP3+ Treg through ATM-AMPK-Sirtuins-Mediated FOXOs Nuclear Translocations.iScience · 2020Article
- CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.Frontiers in immunology · 2020Review
- The dark side of immunotherapy: pancreatic cancer.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic Cancer.Disease markers · 2020Article
- Molecular Screening for Nigericin Treatment in Pancreatic Cancer by High-Throughput RNA Sequencing.Frontiers in oncology · 2020Article
- Virus-like particles for vaccination against cancer.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of key signalling pathways involved in immune-system regulation, along with the development of early pancreatic tumours in mouse models have provided new opportunities for pancreatic cancer treatment and prevention. Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.